Propionic Acidemia Market By Treatment Type (Medical Nutrition and Dietary Management, L-Carnitine Therapy, Antibiotic Therapy, Hyperammonemia Management, Acute Metabolic Crisis Stabilization, Liver Transplantation, Emerging mRNA Therapy); By Diagnostic Approach (Newborn Screening, Biochemical Testing, Molecular Genetic Testing, Enzyme-Activity Testing); By Age Group (Neonates and Infants, Children, Adolescents, Adults); By End User (Specialist Metabolic Centers, Hospitals and Emergency Departments, Diagnostic Laboratories, Transplant Centers, Research and Clinical-Trial Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Propionic Acidemia Market: Crisis Prevention and mRNA Therapy Redefine an Ultra-Rare Care Model An Ultra-Rare Market Built Around Avoiding High-Cost Metabolic Crises

The Global Propionic Acidemia Market was valued at USD 0.62 billion in 2025 and is projected to reach USD 1.18 billion by 2032, expanding at a CAGR of 9.6% during 2026–2032, according to Strategic Market Research.

The market is characterized by a small diagnosed population and a highly specialized care framework. Revenue is concentrated across lifelong metabolic management, medical nutrition, molecular diagnosis, emergency treatment, multisystem monitoring, and liver transplantation. Further expansion depends on the clinical and regulatory progress of disease-modifying therapies designed to reduce the frequency and severity of metabolic crises.

Propionic acidemia results from biallelic pathogenic variants in PCCA or PCCB, which encode the two subunits of mitochondrial propionyl-CoA carboxylase. Reduced enzyme activity prevents the normal metabolism of propionyl-CoA generated from selected amino acids, odd-chain fatty acids, and cholesterol side chains. Toxic metabolites accumulate and can rise rapidly during infection, fasting, surgery, or other catabolic stress. The commercial burden is therefore shaped less by continuous symptom treatment and more by recurrent hospitalization, specialist nutrition, emergency stabilization, and long-term surveillance for neurological, cardiac, renal, hematological, pancreatic, and developmental complications.

 

Diagnosed Patient Numbers Depend More on Screening Than Population Growth

The U.S. Health Resources and Services Administration estimates that approximately 40 affected babies are born in the United States each year. GeneReviews places U.S. birth incidence at approximately 0.14–0.77 cases per 100,000 births, although estimates vary according to screening coverage, case definitions, and study periods.

A systematic epidemiology review reported pooled detection rates of 0.29 per 100,000 newborns in Asia-Pacific, 0.33 in Europe, 0.33 in North America, and 4.24 in the Middle East and North Africa. Individual MENA studies reported 3.6–8.14 cases per 100,000 newborns. Founder variants also produce higher concentrations in Greenlandic Inuit, Amish, Mennonite, Saudi Arabian, and selected Japanese populations. Commercial planning therefore requires referral networks around specialist metabolic centers and high-incidence communities rather than strategies based solely on national population size.

The diagnosed population remains smaller than the biological population in countries without broad newborn screening or rapid metabolic testing. Neonatal deaths may occur before biochemical or molecular confirmation, while milder patients may remain undetected until an infection or another stressor causes a crisis. Expanded tandem mass spectrometry, second-tier metabolite testing, and genetic confirmation can increase identified cases without any change in underlying incidence.

 

Newborn Screening Is the Main Gateway Into Lifelong Care

Newborn screening initially identifies elevated propionylcarnitine, or C3, in dried blood spots. Confirmation uses urine organic acids, plasma acylcarnitines, plasma amino acids, and molecular testing for PCCA and PCCB variants. Enzyme-activity testing may be used when biochemical and genetic findings remain unresolved, although molecular testing now confirms most cases.

Screening is time-sensitive because affected infants may become critically ill before confirmatory results are available. Prematurity, maternal vitamin B12 deficiency, and other metabolic conditions can also produce abnormal C3 findings, increasing demand for rapid second-tier testing. Each confirmed diagnosis initiates genetic counseling, family testing, individualized nutrition planning, emergency protocols, and long-term monitoring across several medical specialties.

Specialist metabolic centers will remain central to the market because they coordinate diagnosis, diet, cardiac surveillance, neurodevelopmental assessment, transplantation, and clinical-trial participation. Concentration of patients in a limited number of centers also creates a relatively defined route for future orphan-drug introduction.

 

Supportive Pharmacotherapy Controls Metabolic Risk but Does Not Restore PCC Activity

Current treatment reduces propionate production, removes accumulated metabolites, controls hyperammonemia, and prevents catabolism. No approved therapy restores normal PCCA or PCCB function. Long-term management combines controlled natural-protein intake, specialized medical foods, medication, emergency illness plans, and surveillance for multisystem complications.

L-carnitine is widely used in chronic and acute management. It combines with accumulated propionyl groups to form propionylcarnitine, which can be excreted through the kidneys. Treatment also replenishes free carnitine depleted through continued metabolite excretion. It supports detoxification but does not correct the defective enzyme.

Metronidazole is used intermittently to suppress anaerobic intestinal bacteria that generate propionate. Lower intestinal propionate production reduces one contributor to metabolic load. Its use is based on specialist practice and treatment guidelines rather than a PA-specific regulatory approval. Repeated exposure requires monitoring because prolonged metronidazole treatment can cause peripheral or optic neuropathy.

Carglumic acid is the principal approved drug associated with propionic acidemia. Hyperammonemia partly develops because propionyl-CoA metabolites inhibit N-acetylglutamate synthesis and reduce urea-cycle activity. Carglumic acid is a structural analogue of N-acetylglutamate that activates carbamoyl phosphate synthetase 1, improving ammonia conversion into urea.

The FDA approved Carbaglu in 2021 as an adjunct to standard care for acute hyperammonemia caused by propionic or methylmalonic acidemia in pediatric and adult patients. It was the first FDA-approved treatment for this complication. The drug controls a life-threatening event but does not reduce the underlying production of propionyl-CoA or restore PCC activity.

Severe crises may also require nitrogen-scavenging medicines, intravenous glucose, insulin when necessary, lipids, temporary protein reduction, intravenous carnitine, and immediate treatment of infection or dehydration. Hemodialysis or another extracorporeal method may be required when ammonia rises rapidly or neurological deterioration continues. These interventions generate substantial hospital costs but are episodic rather than long-term pharmaceutical treatments.

Liver transplantation is considered for recurrent metabolic crises or severe disease despite medical management. It increases functional PCC activity in the liver and can reduce crisis frequency, but it does not correct enzyme deficiency in the brain, heart, kidneys, or other tissues. A 2025 U.S. claims study found that 21 of 191 patients had evidence of liver transplantation. The median age at the earliest observed procedure was 5.6 years. Surgery, donor availability, immunosuppression, rejection, infection, and continued multisystem surveillance restrict transplantation to selected patients.

 

mRNA-3927 Defines the Clinical-Stage Disease-Modifying Pipeline

Based on publicly disclosed company and clinical-trial information, the clinical-stage pipeline is centered on mRNA-3927. Gene-delivery, enzyme-replacement, substrate-reduction, chemical-chaperone, and mitochondrial-protection approaches remain important research areas, but they should not be presented as active clinical pipeline products without a named developer and registered human study.

mRNA-3927 contains two lipid-nanoparticle-encapsulated messenger RNAs. One encodes the normal PCCA alpha subunit and the other encodes the PCCB beta subunit. After uptake by liver cells, both mRNAs are translated into proteins that assemble into functional mitochondrial propionyl-CoA carboxylase. The treatment is intended to provide intracellular enzyme replacement across both PCCA- and PCCB-related disease. Because mRNA expression is temporary, continued benefit requires repeat intravenous administration.

Interim Phase 1/2 results included 16 participants across five dose cohorts. Investigators administered 346 intravenous doses over 15.69 person-years and reported no dose-limiting toxicities. Treatment-emergent adverse events occurred in 15 participants. Among eight participants who had metabolic decompensation during the 12 months before treatment, the preliminary analysis estimated a 70% reduction in event risk during therapy.

The relative-risk estimate was 0.30, but the confidence interval was wide and crossed 1. The small, open-label study compared outcomes with participants’ previous event histories. It provides an early clinical signal rather than definitive evidence of efficacy.

The main Phase 1/2 program is registered as NCT04159103, while NCT05130437 evaluates longer-term safety in previously treated participants. The extension is not a separate pipeline drug. Moderna’s pipeline, updated May 28, 2026, lists mRNA-3927 in Phase 2. The registrational study has reached target enrollment, with a potential data readout expected during 2026. No pivotal efficacy result had been publicly reported through August 5, 2026.

In January 2026, Moderna granted Recordati worldwide commercialization rights while retaining clinical-development responsibility through approval. Recordati will lead commercialization, while Moderna will continue manufacturing the product. The transaction closed on March 16, 2026 and included a USD 50 million upfront payment, up to USD 110 million in development and regulatory milestones, further commercial payments, and tiered royalties. Recordati’s existing organic-acidemia franchise provides an established specialist channel for future market access.

 

Age-Stratified Disease Burden and Biomarker Validation Will Shape Commercial Uptake

The propionic acidemia population is clinically heterogeneous and should not be treated as a single orphan-disease cohort. Treatment needs and outcomes vary by age. A 2025 U.S. claims study of 191 patients found 31.4% had at least one metabolic decompensation over 2.7 years, with an overall rate of 0.44 events per patient-year and an average 8.5-day hospital stay per event. Events were highest in children aged 3–6 years (1.38 per patient-year) and lower in adolescents (0.14) and adults (0.22).

Young children show the greatest opportunity to reduce metabolic crises, ICU use, and hospital days, while adults face more chronic cardiac, neurological, psychiatric, renal, and nutritional complications. This supports different pediatric and adult value propositions. The same study showed younger patients more often had metabolic and feeding complications, while older patients more often had cardiomyopathy, psychosis, and autism.

Metabolic crises are important but variable endpoints influenced by infections and age distribution, requiring long studies or high-risk populations. Claims data are also limited by coding-based identification and small subgroup sizes.

Biomarkers such as 3-hydroxypropionic acid, methylcitric acid, propionylcarnitine, ammonia, and others may help track disease activity. A 2026 study found lower 3-hydroxypropionic acid and propionylcarnitine were linked to fewer crises, but validation is still needed.

Clinical outcomes like crisis reduction, hospital days, and neurological and functional improvement will remain central for regulators and payers. This increases the importance of natural-history studies, registries, and standardized outcome measures. The Propionic Acidemia Foundation supports such infrastructure through an international registry and biobank, alongside research into multiple therapeutic approaches beyond enzyme replacement.

 

Market Outlook

Propionic acidemia will remain a small-volume, high-complexity market. Growth will come from improved newborn screening, wider molecular confirmation, longer survival, structured specialist follow-up, and the possible introduction of disease-modifying treatment. Medical nutrition, carnitine, antibiotics, hyperammonemia treatment, molecular diagnostics, acute hospital care, and transplantation will remain important because no intervention is expected to eliminate multisystem monitoring.

The leading near-term event is the registrational evidence for mRNA-3927. A meaningful reduction in metabolic decompensation, supported by biomarker improvement and acceptable repeat-dose safety, would shift expenditure from emergency stabilization toward chronic enzyme restoration. Weak or inconsistent event reduction would preserve the current care model centered on diet, supplements, hyperammonemia control, hospital intervention, and transplantation.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 0.62 Billion
Revenue Forecast in 2032	USD 1.18 Billion
Overall Growth Rate	CAGR of 9.6% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Treatment Type, By Diagnostic Approach, By Age Group, By End User, By Geography
By Treatment Type	Medical Nutrition and Dietary Management, L-Carnitine Therapy, Antibiotic Therapy, Hyperammonemia Management, Acute Metabolic Crisis Stabilization, Liver Transplantation, Emerging mRNA Therapy
By Diagnostic Approach	Newborn Screening, Biochemical Testing, Molecular Genetic Testing, Enzyme-Activity Testing
By Age Group	Neonates and Infants, Children, Adolescents, Adults
By End User	Specialist Metabolic Centers, Hospitals and Emergency Departments, Diagnostic Laboratories, Transplant Centers, Research and Clinical-Trial Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Saudi Arabia, UAE, Brazil, Mexico, South Africa
Market Drivers	Expansion of newborn screening and molecular confirmation, rising demand for metabolic-crisis prevention, increasing use of specialist medical nutrition and hyperammonemia management, progress of repeat-dose mRNA therapy, stronger rare-disease referral and registry infrastructure
Customization Option	Available upon request